

Correspondence

Reply

To the Editor:

We thank Dr Dreyfus¹ for his comment on our report.² We did monitor patients for thyroid function and did not find an increase in levels of free T3, free T4, or thyroid-stimulating hormone in patients treated with omalizumab. We also monitored patients for antibody levels and did not find a significant increase in anti-thyroid-stimulating hormone antibody levels in patients treated with omalizumab.

*Marcus Maurer, MD
for the X-CUISITE study team*

From Charité–Universitätsmedizin Berlin, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany. E-mail: marcus.maurer@charite.de.

Disclosure of potential conflict of interest: M. Maurer received honoraria for lectures and research support from Novartis.

REFERENCES

1. Dreyfus DH. Monitoring of thyroid function in patients who exhibit IgE against thyroperoxidase while taking omalizumab? *J Allergy Clin Immunol* 2012;129:XXX-XXX.
2. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. *J Allergy Clin Immunol* 2011;128:202-9.

doi:10.1016/j.jaci.2011.10.041